3 completed, 2 terminated, 2 unknown, 1 recruiting. 3 Phase 3, 1 Not applicable, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Sorafenib: new trials by email Literature Review of Sorafenib trials Research Report on Sorafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib Gilteritinib, Sorafenib - Acute Myeloid Leukemia (AML), FLT3-ITD Mutation | Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 594 | 2026-05-01 | 2026-03-20 |
| A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET sorafenib, gefitinib - Pancreatic Neuroendocrine Neoplasm, Sorafenib | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 20 | 2024-09-30 | 2025-01-10 | |
| Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT Radiotherapy plus Toripalimab, Sorafenib - Radiotherapy, Toripalimab | Phase 3 | Terminated | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 36 | 2021-03-02 | 2025-02-26 |
| TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC TACE combined with sorafenib and PD-1 mAb - Hepatocellular Carcinoma, Liver Neoplasms | Phase 2 | Completed | Sichuan Cancer Hospital and Research Institute | 27 | 2020-09-14 | 2024-06-25 |
| Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC Hepatocellular Carcinoma, Sorafenib | Terminated | University Hospital Tuebingen | 2 | 2019-11-01 | 2024-04-01 | |
| TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma TACE+sorafenib, TACE - Hepatocellular Carcinoma, Sorafenib | Phase 3 | Completed | Sun Yat-sen University | 162 | 2019-10-02 | 2024-02-28 |
| Combined Treatment of RFA and Sorafenib on Recurrent HCC RFA + Sorafenib, RFA - HCC, Radiofrequency Ablation | Not applicable | Unknown | Southwest Hospital, China | 430 | 2015-01-01 | 2017-03-28 |
| Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) hepatic resection, transcatheter hepatic arterial chemoembolization, sorafenib - Hepatectomy, Hepatocellular Carcinoma | Phase 4 | Completed | Sun Yat-sen University | 180 | 2011-01-01 | 2018-09-11 |
Carcinoma, Hepatocellular (4) · Liver Neoplasms (2) · Adenoma, Islet Cell (1) · Digestive System Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Liver Diseases (1)
Neoplasms (6) · Neoplasms by Histologic Type (6) · Digestive System Diseases (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Adenocarcinoma (4) · Carcinoma (4) · Digestive System Neoplasms (4) · Liver Diseases (3) · Liver Neoplasms (2) · Adenoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1)
Sorafenib (6) · Gefitinib (1) · Hepatectomy (1) · Radiofrequency Ablation (1) · Radiotherapy (1) · gilteritinib (1) · toripalimab (1)
Sun Yat-sen University (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Sichuan Cancer Hospital and Research Institute (1) · Southwest Hospital, China (1) · The First Affiliated Hospital of Soochow University (1) · University Hospital Tuebingen (1)
China (7) · Germany (1)
Jiang Long, M.D. (1) · Jiuliang Yan, M.D. (1) · Kuansheng Ma, MD,Ph.D (1) · Michael Bitzer, MD (1) · Ming Kuang, PhD (1) · Minshan Chen, M.D. (1) · Nisar P Malek, MD (1)
PMID 19704057, PMID 26703889, PMID 30833272, PMID 31555796, PMID 33788183, PMID 34012671, PMID 34388377, PMID 35348774, PMID 36140756, PMID 36891979, PMID 37774329, PMID 38610840, PMID 38900435